TrianglePembrolizumab (NCT04318717)
Pembrolizumab trial for Mucosal Melanoma of the Head and Neck (NCT04318717). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for patients aged 16 or older with resected mucosal melanoma, without metastatic disease or previous radiation to the treatment area.
The idea: pembrolizumab blocks PD-1, releasing an immune brake, while radiation treats the surgical area. Pembrolizumab is infused every three weeks for up to one year. Radiation totals 30 gray over five sessions and begins within 90 days after surgery. Researchers assess tumor control and safety against historical radiation-only results.
This phase 2 study plans 20 patients. George Ansstas leads at Washington University, St. Louis, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.